Triptorelin Injection​ (Decapeptyl​)

Buy Triptorelin 11.25mg

Triptorelin Injection: A Comprehensive Product Overview

Triptorelin Injection is a synthetic decapeptide analogue of naturally occurring gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH) . As a potent GnRH receptor agonist, it plays a pivotal role in managing hormone-dependent conditions by paradoxically suppressing the reproductive hormonal axis following an initial stimulatory phase . This article provides a detailed description of triptorelin, including its mechanism of action, clinical applications, available formulations, and key safety considerations.

Mechanism of Action: The Agonist Paradox

The pharmacology of triptorelin is defined by its biphasic effect on the hypothalamic-pituitary-gonadal (HPG) axis. As a GnRH agonist, triptorelin has a higher potency and longer half-life than the endogenous hormone, leading to continuous stimulation of pituitary GnRH receptors .

1. Initial Stimulation (The “Flare” Effect): Upon administration, triptorelin injection acts as an agonist, causing a transient, sharp increase in the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary . This surge leads to a corresponding temporary elevation in gonadal sex hormone levels—testosterone in males and estradiol in females .

2. Receptor Desensitization and Suppression: With continued, sustained exposure, the constant stimulation leads to the down-regulation of GnRH receptors on pituitary gonadotrophs. The pituitary becomes desensitized, resulting in a profound and sustained decrease in LH and FSH secretion .

This leads to a near-complete suppression of gonadal steroid production, creating a state of reversible “medical castration” . This suppression is typically achieved within 3 to 4 weeks of continuous therapy .

Clinical Applications Of Triptorelin Injection

The unique ability of triptorelin to induce reversible chemical castration makes it a valuable therapeutic agent for a range of hormone-sensitive conditions. Its regulatory approvals reflect its established efficacy and safety profile in specific patient populations.

Advanced Prostate Cancer (Trelstar®)

In men with advanced hormone-dependent prostate cancer, triptorelin is indicated for palliative treatment . By reducing serum testosterone to castrate levels, the drug effectively slows the progression of the disease . Trelstar is available in several extended-release intramuscular formulations, providing flexibility in dosing schedules:

· Trelstar 3.75 mg: Administered monthly (every 28 days) .
· Trelstar 11.25 mg: Administered every 12 weeks.
· Trelstar 22.5 mg: Administered every 24 weeks .

Central Precocious Puberty (Triptodur®)

For pediatric patients, triptorelin is approved to treat central precocious puberty (CPP), a condition where puberty begins abnormally early (before age 9 in girls and age 10 in boys) . Triptorelin suppresses the premature activation of the HPG axis, thereby halting the progression of early sexual development and allowing for more appropriate linear growth until the normal age of puberty. Triptodur is formulated as a long-acting 22.5 mg injection administered by a healthcare professional once every 24 weeks . It is indicated for use in children aged 2 years and older .

Other Therapeutic Uses

While not approved by the FDA for these indications, triptorelin is widely used globally and is a well-recognized treatment for other conditions, including:

· Endometriosis: To suppress ovarian function and reduce endometriotic lesions .
· Uterine Fibroids (Leiomyomas): For preoperative reduction of myoma size and associated symptoms like bleeding and pain .
· Assisted Reproduction: For controlled ovarian hyperstimulation in in vitro fertilization (IVF) protocols .

Important Safety Information and Warnings

The use of triptorelin is associated with several significant side effects and warnings that necessitate careful medical supervision.

· Tumor Flare: The initial, transient rise in testosterone can cause a temporary worsening of symptoms in patients with prostate cancer. This “tumor flare” can manifest as increased bone pain, urinary tract obstruction, or complications in patients with spinal metastases . This risk is typically managed by co-administering an anti-androgen during the first few weeks of therapy .

· Metabolic and Cardiovascular Effects: Long-term androgen deprivation therapy is associated with an increased risk of metabolic changes, such as hyperglycemia, diabetes, and hyperlipidemia, as well as potential cardiovascular risks like myocardial infarction and stroke . Regular monitoring of glucose and lipid profiles is recommended.

· Bone Mineral Density (BMD): The suppression of sex hormones inevitably leads to a loss of bone mineral density, which can increase the risk of osteoporosis and fractures . This is a particular concern in children undergoing treatment for CPP and women treated for endometriosis. In children, bone mass accrual typically resumes after treatment cessation.

· Other Common Adverse Reactions: The most frequently reported side effects are a direct result of the drug’s pharmacological action and include hot flushes (reported in up to 50-58% of male patients), erectile dysfunction, decreased libido, and testicular atrophy in men . Injection site pain and headache are also common .

· Hypersensitivity: Triptorelin is contraindicated in patients with a known hypersensitivity to GnRH or its analogues, as anaphylactic shock and angioedema have been reported.

· Psychiatric Effects: Mood changes, including depression, irritability, and emotional lability, have been reported with the use of GnRH agonists

· Contraindications: It is contraindicated in women who are pregnant or breastfeeding

Conclusion

It is a highly effective and potent GnRH agonist that leverages a paradoxical mechanism to reversibly suppress the reproductive hormonal axis. Its primary approved indications—treating advanced prostate cancer in adults and central precocious puberty in children—underscore its versatility in managing hormone-dependent pathologies. However, its powerful endocrine effects require careful patient selection, education, and monitoring to manage the significant risks of tumor flare, metabolic syndrome, bone loss, and other adverse effects.